Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | GRIK1 | P39086 | 4/20 | 0.51 |
| ▸ | GRIK2 | Q13002 | 4/20 | 0.51 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.51 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.51 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.46 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.44 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.44 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1875642 | 1.00 | CA2 (0.52) | CA2MAPK1GRIK1GRIK2SLC1A2 | |
| SCHEMBL7541186 | 0.98 | GRIK1 (0.53) | CA2MAPK1GRIK1GRIK2SLC1A2 | |
| SCHEMBL28713474 | 0.94 | CA2 (0.59) | CA2MAPK1GRIK1GRIK2SLC1A2 | |
| SCHEMBL28891394 | 0.88 | GRIK1 (0.44) | CA2MAPK1GRIK1GRIK2SLC1A2 | |
| SCHEMBL13679533 | 0.86 | CHRM1 (0.60) | CA2MAPK1GRIK1GRIK2SLC1A2 | |
| SCHEMBL9122878 | 0.86 | CHRM1 (0.60) | CA2MAPK1GRIK1GRIK2SLC1A2 | |
| SCHEMBL9049404 | 0.86 | CHRM1 (0.60) | CA2MAPK1GRIK1GRIK2SLC1A2 | |
| SCHEMBL6552465 | 0.84 | GRIK1 (0.50) | GRIK1GRIK2FFAR1MAPTFFAR4 | |
| SCHEMBL28085929 | 0.84 | FFAR1 (0.56) | CA2MAPK1GRIK1GRIK2SLC1A2 | |
| SCHEMBL7062779 | 0.84 | GRIK1 (0.50) | CA2MAPK1GRIK1GRIK2SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11975032-B2 | Medicament for liver regeneration and for treatment of liver failure | MEDIZINISCHE HOCHSCHULE HANNOVER (DE) | 2024-05-07 | — | — | US | disclosed |
| US-11773064-B2 | 4-carboxamido-isoindolinone derivatives as selective PARP-1 inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2023-10-03 | — | — | US | disclosed |
| US-20220363636-A1 | 4-CARBOXAMIDO-ISOINDOLINONE DERIVATIVES AS SELECTIVE PARP-1 INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2022-11-17 | — | — | US | disclosed |
| US-11420940-B2 | 4-carboxamido-isoindolinone derivatives as selective parp-1 inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2022-08-23 | — | — | US | disclosed |
| US-20200138832-A1 | COMPOUNDS AND PRODRUGS THEREOF FOR THE TREATMENT OF OPHTHALMIC DISEASE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2020-05-07 | — | — | US | disclosed |
| US-20180318321-A1 | NON-SURGICAL METHOD OF TREATMENT FOR CATARACT | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2018-11-08 | — | — | US | disclosed |
| US-9512463-B2 | Methods and compositions for assaying the activity of one or more lysosomal enzymes | UNIVERSITY OF WASHINGTON (US) | 2016-12-06 | — | — | US | disclosed |
| EP-2454237-B1 | 3-OXO-2,3,-DIHYDRO-1H-ISOINDOLE-4-CARBOXAMIDES WITH SELECTIVE PARP-1 INHIBITION | NERVIANO MEDICAL SCIENCES SRL (IT) | 2016-09-07 | — | — | EP | disclosed |
| EP-2802670-A1 | LYSOSOMAL ENZYME ASSAY METHODS AND COMPOSITIONS | University of Washington (US) | 2014-11-19 | — | — | EP | disclosed |
| US-20140031327-A1 | NON-SURGICAL METHOD OF TREATMENT FOR CATARACT | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-01-30 | — | — | US | disclosed |
| WO-2013070953-A1 | LYSOSOMAL ENZYME ASSAY METHODS AND COMPOSITIONS | UNIVERSITY OF WASHINGTON (US) | 2013-05-16 | — | — | WO | disclosed |
| EP-2454237-A1 | 3-0X0-2, 3, -DIHYDRO-1H-ISOINDOLE-4-CARBOXAMIDES WITH SELECTIVE PARP-1 INHIBITION | Nerviano Medical Sciences S.r.l. (IT) | 2012-05-23 | — | — | EP | disclosed |
| WO-2011006803-A9 | 3-0X0-2, 3, -DIHYDRO-1H-ISOINDOLE-4-CARBOXAMIDES WITH SELECTIVE PARP-1 INHIBITION | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773064-B2 | 4-carboxamido-isoindolinone derivatives as selective PARP-1 inhibitors | PARP1, PARP2, PARP12 | CA2 4176/4885MAPK1 1291/4885GRIK1 1073/4885 |
| US-20200138832-A1 | COMPOUNDS AND PRODRUGS THEREOF FOR THE TREATMENT OF OPHTHALMIC DISEASE | CRYAB, CRYAA, CRYZ | CA2 1226/4885MAPK1 3389/4885GRIK1 4561/4885 |
| US-11420940-B2 | 4-carboxamido-isoindolinone derivatives as selective parp-1 inhibitors | PARP1, PARP2, PARP11 | CA2 4223/4885MAPK1 2321/4885GRIK1 1120/4885 |
| US-20220363636-A1 | 4-CARBOXAMIDO-ISOINDOLINONE DERIVATIVES AS SELECTIVE PARP-1 INHIBITORS | PARP1, PARP2, PARP12 | CA2 4166/4885MAPK1 1275/4885GRIK1 1072/4885 |
| US-11975032-B2 | Medicament for liver regeneration and for treatment of liver failure | PYGL, HNF4A, ATF1 | CA2 3786/4885MAPK1 59/4885GRIK1 1477/4885 |
| US-20140031327-A1 | NON-SURGICAL METHOD OF TREATMENT FOR CATARACT | CRYAB, CRYZ, CRYAA | CA2 296/4885MAPK1 2575/4885GRIK1 4506/4885 |
| US-20180318321-A1 | NON-SURGICAL METHOD OF TREATMENT FOR CATARACT | CRYAB, CRYZ, CRYAA | CA2 296/4885MAPK1 2575/4885GRIK1 4506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.